Drug Monograph
Alprazolam
Xanax, Xanax XR
Pharmacokinetic Profile
Half-Life
11.2 h (6.3-26.9 h)
Metabolism
CYP3A4 (major)
Protein Binding
80%
Bioavailability
80-100%
Volume of Distribution
0.9–1.2 L/kg
Tmax
1-2 h (IR); plateau 5-11 h (XR)
Clinical Information
Drug Class
Benzodiazepine
Available Doses
IR: 0.25, 0.5, 1, 2 mg; XR: 0.5, 1, 2, 3 mg
Route
Oral
Renal Adjustment
Not required
Hepatic Adjustment
Yes — reduce dose
Pregnancy
Risk of neonatal sedation/withdrawal
Lactation
Not recommended
Schedule
C-IV (Controlled)
Generic Available
Yes
Black Box Warning
Yes — 3 warnings
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Generalized anxiety disorder (GAD) | Adults | Monotherapy (acute treatment) | FDA Approved |
| Panic disorder with or without agoraphobia | Adults | Monotherapy | FDA Approved |
Alprazolam is one of the most widely prescribed benzodiazepines, primarily used for acute management of anxiety and panic symptoms. For GAD, its efficacy has been demonstrated in short-term trials of up to 4 weeks; long-term efficacy beyond 4 months has not been systematically evaluated. For panic disorder, controlled trials used dosages up to 10 mg/day, with mean effective dosages of 5–6 mg/day. Current guidelines generally recommend benzodiazepines as second- or third-line agents after SSRIs and SNRIs, reserving alprazolam for patients who have not responded adequately to first-line treatments or who require rapid symptom relief while awaiting onset of antidepressant effect.
Off-Label Uses
Insomnia (short-term): Occasionally used when anxiety-related insomnia predominates. Evidence quality: Low.
Anticipatory anxiety (e.g., procedural, dental): Single-dose use before procedures. Evidence quality: Moderate (clinical practice consensus).
Chemotherapy-induced anticipatory nausea: Limited data supporting use as an adjunct. Evidence quality: Low.
Dosing
Adult Dosing — Immediate-Release Tablets
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Generalized anxiety — mild to moderate | 0.25 mg TID | 0.5–1 mg TID | 4 mg/day | Titrate q3–4 days; use lowest effective dose Reassess need after 4 months |
| Generalized anxiety — moderate to severe | 0.5 mg TID | 0.5–1.5 mg TID | 4 mg/day | Reserve higher doses for documented non-responders Goal: shortest possible duration |
| Panic disorder — initial stabilisation | 0.5 mg TID | 1–2 mg TID | 10 mg/day | Titrate by ≤1 mg/day q3–4 days; mean effective dose in trials: 5–6 mg/day Interdose anxiety may require more frequent dosing |
| Panic disorder — long-term management | Stable dose from titration | Lowest effective dose | 10 mg/day | Periodically reassess; doses >4 mg/day carry greater dependence risk Attempt supervised taper after sustained remission |
| Anticipatory/procedural anxiety | 0.25–0.5 mg single dose | N/A (single use) | 1 mg single dose | Give 30–60 min before procedure Off-label; avoid driving after |
Adult Dosing — Extended-Release Tablets (Xanax XR)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Panic disorder — XR formulation | 0.5–1 mg once daily | 3–6 mg once daily | 10 mg/day | Give in the morning; swallow whole, do not crush Titrate by ≤1 mg/day q3–4 days |
Special Populations
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Elderly patients (≥65 years) | 0.25 mg BID–TID | Titrate cautiously | Lowest effective | Higher plasma levels due to reduced clearance (t½ ~16.3 h) Increased fall risk; use ataxia-safe doses |
| Hepatic impairment | 0.25 mg BID–TID | Titrate cautiously | Lowest effective | Alcoholic liver disease: mean t½ 19.7 h (range 5.8–65.3 h) Accumulation risk is substantial |
| Co-administration with ritonavir | 50% of usual dose | Resume target after 10–14 days | Standard | Short-term ritonavir inhibits CYP3A4; chronic use induces it Complex time-dependent interaction |
Clinical Pearl: Tapering
To discontinue alprazolam, reduce by no more than 0.5 mg every 3 days. Many patients benefit from even slower reductions. Doses above 4 mg/day are associated with significantly greater difficulty tapering. In controlled trials, 7–29% of patients could not fully discontinue therapy. A protracted withdrawal syndrome lasting weeks to over 12 months has been documented.
Pharmacology
Mechanism of Action
Alprazolam is a triazolobenzodiazepine that enhances the inhibitory activity of gamma-aminobutyric acid (GABA) at the GABA-A receptor. It binds to the benzodiazepine site located at the interface of the alpha and gamma subunits, increasing the frequency of chloride channel opening when GABA is present. This allosteric potentiation of GABAergic neurotransmission produces anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. The triazole ring fused to the benzodiazepine structure contributes to its relatively high potency and rapid onset of action compared to other benzodiazepines. Research suggests that effects mediated through alpha-2 and alpha-3 subunit-containing GABA-A receptors are primarily responsible for the anxiolytic properties, while the alpha-1 subunit mediates sedation.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid; bioavailability 80–100%; Tmax 1–2 h (IR); XR maintains plateau concentrations from 5–11 h post-dose; linear pharmacokinetics over 0.5–3 mg | Effects felt within 15–30 minutes of oral dosing; food does not meaningfully affect extent of absorption |
| Distribution | 80% protein bound (mainly albumin); crosses placenta; excreted in breast milk | Hypoalbuminaemia may increase free drug fraction; avoid late in pregnancy |
| Metabolism | Extensively hepatic via CYP3A4; active metabolites (4-hydroxy, alpha-hydroxy) at <4% parent levels | Strong CYP3A4 inhibitors are contraindicated (ketoconazole increases AUC ~4-fold); smokers may have up to 50% lower concentrations |
| Elimination | Renal (urine, parent + metabolites); t½ 11.2 h (healthy adults), 16.3 h (elderly), 19.7 h (hepatic disease), 21.8 h (obese) | Prolonged half-life in elderly, obese, and hepatically impaired patients necessitates dose reduction and careful monitoring for accumulation |
Side Effects
≥10%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Drowsiness / Sedation | 41–77% | Most frequent effect; dose-related; higher in panic disorder trials due to higher doses used (up to 10 mg/day); typically attenuates within 1–2 weeks |
| Fatigue / Tiredness | 49% | Reported in panic disorder trials; overlaps with sedation; usually improves with continued therapy |
| Impaired Coordination | 40% | Significant fall risk in elderly; contributes to driving impairment and motor vehicle accidents |
| Memory Impairment | 33% | Anterograde amnesia; dose-dependent; little tolerance develops to cognitive effects over time |
| Cognitive Disorder | 29% | Difficulty concentrating, slowed thinking; additive with other CNS depressants |
| Increased Appetite / Weight Gain | 27–33% | Clinically relevant weight change in long-term panic disorder treatment |
| Constipation | 26% | Reported in panic disorder trials; manage with increased fluids and fibre |
| Dysarthria | 23% | Slurred speech; dose-related; more prominent at higher doses used in panic disorder |
| Light-headedness | 21% | Common in anxiety disorder trials; often present at initiation |
| Dry Mouth | 15% | From anxiety trials; usually mild and self-limiting |
| Decreased Libido | 14% | May be under-reported; enquire actively at follow-up |
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Confusional State | 10% | More pronounced in elderly and with concomitant CNS depressants |
| Increased Libido | 8% | Paradoxical to decreased libido; attributed to disinhibition |
| Sexual Dysfunction | 7% | Various complaints including anorgasmia; may be difficult to distinguish from underlying disorder |
| Increased Salivation | 4–6% | Unexpected given typical benzodiazepine drying effects |
| Hypotension | 5% | Orthostatic component possible; warn patients when rising |
| Dermatitis / Rash | 4–11% | Higher rates in panic disorder trials; rarely requires discontinuation |
| Disinhibition | 3% | May manifest as inappropriate behaviour; higher risk with pre-existing personality disorders |
| Dizziness | 2% | Distinct from light-headedness; usually transient |
| Incontinence | 2% | Urinary; secondary to muscle relaxation; more common in elderly |
Serious
Serious Adverse Effects (Any Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Physical Dependence / Withdrawal Seizures | Common with prolonged use | On abrupt discontinuation; risk increases >12 weeks use | Never discontinue abruptly; taper by ≤0.5 mg q3 days; seizures reported even at therapeutic doses |
| Respiratory Depression | Rare alone; common with opioid co-use | Hours after dose, especially with concomitant CNS depressants | Discontinue immediately; supportive care; flumazenil if needed (use cautiously — may precipitate seizures) |
| Paradoxical Reactions (rage, aggression, agitation) | Rare | Any time during treatment | Discontinue alprazolam; higher risk in borderline personality disorder, substance use history |
| Suicidal Ideation (in depression) | Uncommon; risk elevated in comorbid depression | Any time, especially early treatment or discontinuation | Limit prescription quantity; monitor closely; consider psychiatric referral |
| Angioedema | Very rare (post-marketing) | Any time | Permanent discontinuation; emergency treatment if airway involvement |
| Stevens-Johnson Syndrome | Very rare (post-marketing) | Days to weeks | Immediate discontinuation; dermatology/burn unit referral |
| Hepatic Failure / Hepatitis | Very rare (post-marketing) | Variable | Discontinue; monitor LFTs; hepatology consultation |
| Neonatal Sedation / Withdrawal (NOWS) | Expected with late-pregnancy exposure | Birth / neonatal period | Monitor neonate for respiratory depression, hypotonia, feeding difficulties, and withdrawal signs |
Discontinuation
Discontinuation Rates
Immediate-Release (Panic Disorder)
7–29% could not fully taper
Key finding: Doses >4 mg/day associated with greater difficulty tapering to zero
Extended-Release (Panic Disorder)
~17% vs 8% placebo
Top reasons: Sedation (7.5%), depression (2.5%), somnolence (3.2%), dysarthria (2.1%)
| Discontinuation-Emergent Symptom | Incidence | Context |
|---|---|---|
| Insomnia | 29.5% | Most common withdrawal symptom; may be difficult to distinguish from rebound anxiety |
| Anxiety (rebound/withdrawal) | 19.2% | Can exceed baseline severity; usually time-limited |
| Light-headedness | 19.3% | Vestibular-type symptoms during taper |
| Fatigue / Tiredness | 18.4% | Paradoxical given stimulant properties of withdrawal |
| Abnormal Involuntary Movement | 17.3% | Includes tremor, myoclonus; dose-related |
| Headache | 17.0% | Tension-type predominates during withdrawal |
| Nausea / Vomiting | 16.5% | GI disturbance common during taper |
| Sweating | 14.4% | Autonomic hyperactivity marker |
| Weight Loss | 13.3% | Often accompanies decreased appetite |
| Tachycardia | 12.2% | Autonomic rebound; consider cardiac monitoring in patients with heart disease |
Managing Sedation — The Most Common Reason for Dose Adjustment
Drowsiness and sedation affect up to 77% of patients at the higher doses used in panic disorder. Starting at the lowest recommended dose and titrating slowly reduces impact. Advise patients that sedation typically improves over 1–2 weeks but that tolerance to cognitive impairment develops minimally. Driving and operating machinery must be avoided until the patient’s individual response is established.
Drug Interactions
Alprazolam is metabolised almost exclusively by CYP3A4. Drugs that inhibit or induce this pathway can profoundly alter alprazolam exposure. Concomitant use with strong CYP3A4 inhibitors (except ritonavir) is contraindicated. Additive CNS depression occurs with all sedating agents.
Major
Opioids (all)
MechanismAdditive CNS and respiratory depression via GABA-A and mu-opioid receptor synergy
EffectProfound sedation, respiratory depression, coma, death
ManagementAvoid if possible; if essential, use lowest doses and shortest duration; close monitoring mandatory
FDA Boxed Warning
Major
Ketoconazole / Itraconazole / Clarithromycin
MechanismStrong CYP3A4 inhibition
EffectKetoconazole increases alprazolam AUC 3.98-fold; itraconazole 2.70-fold
ManagementContraindicated — use alternative antifungal (e.g., terbinafine for dermatophytes) or alternative anxiolytic
FDA PI
Major
Alcohol
MechanismAdditive GABAergic CNS depression
EffectMarked sedation, impaired motor function, respiratory depression
ManagementAbsolute avoidance advised; counsel all patients at every visit
FDA PI
Moderate
Nefazodone
MechanismCYP3A4 inhibition
EffectDoubles alprazolam plasma concentrations (AUC increased 1.98-fold)
ManagementReduce alprazolam dose by 50% when co-prescribing; monitor for excess sedation
FDA PI
Moderate
Fluvoxamine
MechanismCYP3A4 inhibition
EffectAUC increased 1.96-fold; approximately doubles Cmax; clearance decreased 49%; half-life increased 71%
ManagementReduce alprazolam dose by 50%; prefer sertraline or escitalopram which have minimal CYP3A4 impact
FDA PI
Moderate
Ritonavir
MechanismComplex time-dependent: short-term CYP3A4 inhibition then induction
EffectShort-term: AUC increased ~2.5-fold; chronic (>10–14 days): net effect neutral
ManagementHalve alprazolam dose at initiation; resume full dose after 10–14 days of ritonavir
FDA PI
Moderate
Carbamazepine / Phenytoin
MechanismCYP3A4 induction
EffectCarbamazepine more than doubles alprazolam oral clearance; half-life shortened from ~17 h to ~8 h
ManagementHigher alprazolam doses may be required; consider alternative benzodiazepine not CYP3A4-dependent (e.g., lorazepam)
FDA PI
Moderate
Digoxin
MechanismReduced renal or non-renal clearance of digoxin (mechanism not fully established)
EffectElevated digoxin levels, especially in patients ≥65 years
ManagementMonitor digoxin serum concentrations; dose-adjust digoxin if necessary
FDA PI
Moderate
Cimetidine
MechanismCYP3A4 inhibition
EffectCmax increased 82%, clearance decreased 42%, half-life increased 16%
ManagementConsider dose reduction of alprazolam; use alternative acid suppressant (famotidine or a PPI) with less CYP3A4 impact
FDA PI
Moderate
Erythromycin
MechanismModerate CYP3A4 inhibition
EffectAUC increased 1.61-fold
ManagementConsider dose reduction; use azithromycin as an alternative macrolide (minimal CYP3A4 effect)
FDA PI
Minor
Fluoxetine
MechanismWeak CYP3A4 inhibition
EffectCmax increased 46%, clearance decreased 21%; modest psychomotor impairment increase
ManagementUsually clinically manageable; monitor for excess sedation; no routine dose change needed
FDA PI
Minor
Oral Contraceptives
MechanismMild CYP3A4 inhibition
EffectCmax increased 18%, clearance decreased 22%, half-life increased 29%
ManagementNo dose adjustment typically needed; be aware if patient reports increased sedation
FDA PIMonitoring
-
Sedation Level
Each visit during titration; then q3 months
Routine Assess daytime sedation, psychomotor function, and driving safety. Use standardised drowsiness scales if available. -
Abuse / Misuse Assessment
Baseline, each visit
Routine Screen for risk factors before prescribing (substance use history, family history). Monitor for early refill requests, dose escalation, or obtaining from multiple prescribers. -
Mood / Suicidality
Each visit, especially with comorbid depression
Routine Benzodiazepines may worsen depression. Limit prescription quantity in patients with depressive symptoms or suicidal ideation. -
Cognitive Function
q3–6 months in long-term use
Routine Assess for memory impairment, attention deficits, and functional decline, especially in elderly patients. -
Fall Risk (Elderly)
Baseline, then q3 months
Routine Impaired coordination and ataxia contribute to falls. Use Timed Up and Go or similar tool. Consider deprescribing if falls occur. -
Respiratory Function
Baseline; ongoing if pulmonary disease
Trigger-based Reports of death in patients with severe pulmonary disease shortly after initiation. Avoid or use extreme caution in COPD, sleep apnoea. -
Hepatic Function
Baseline if liver disease suspected; as clinically indicated
Trigger-based Elevated hepatic enzymes and hepatitis reported post-marketing. Patients with alcoholic liver disease have prolonged half-life. -
Treatment Duration Review
q3 months
Routine Reassess continued need at every visit. GAD efficacy not established beyond 4 months; PD efficacy beyond 10 weeks. Document ongoing clinical justification.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to alprazolam or any other benzodiazepine (angioedema has been reported)
- Concomitant strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) — except ritonavir (see dose modification)
- Acute narrow-angle glaucoma (class-wide benzodiazepine contraindication)
Relative Contraindications (Specialist Input Recommended)
- Active or recent substance use disorder — high abuse potential; if used, requires documented risk-benefit analysis and close monitoring
- Severe hepatic impairment — markedly prolonged half-life increases accumulation risk
- Severe respiratory disease (COPD, sleep apnoea) — deaths reported shortly after initiation in patients with severe pulmonary disease
- Major depressive disorder (untreated) — benzodiazepines may worsen depression; limit prescription quantity
- Pregnancy (late trimester) — risk of neonatal sedation and withdrawal syndrome
Use with Caution
- Elderly patients — increased sensitivity, higher plasma levels, fall risk
- Obesity — mean half-life 21.8 h (nearly double); monitor for accumulation
- History of paradoxical reactions to benzodiazepines
- Patients taking other CNS depressants — including anticonvulsants, antihistamines, sedating antidepressants
- Smokers — concentrations reduced up to 50%; may need dose adjustment
FDA Boxed Warning
Risks from Concomitant Use with Opioids
Combined use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with no adequate alternative. Use lowest effective doses for the shortest possible duration. Monitor closely for respiratory depression and sedation.
FDA Boxed Warning
Abuse, Misuse, and Addiction
Alprazolam exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Assess each patient’s risk before prescribing and throughout treatment. Even therapeutic use may lead to physical dependence and addiction.
FDA Boxed Warning
Dependence and Withdrawal Reactions
Continued use may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dose reduction can precipitate life-threatening withdrawal reactions including seizures. Use a gradual taper to discontinue. A protracted withdrawal syndrome lasting weeks to more than 12 months has been described.
Patient Counselling
Purpose of Therapy
Alprazolam is prescribed to reduce anxiety symptoms or to control panic attacks. It works by calming overactive nerve signals in the brain. It is intended as a short-term treatment and is most effective when combined with psychological therapies such as cognitive behavioural therapy. Because the body can become physically dependent on this medication, ongoing treatment must be reviewed regularly with your prescriber.
How to Take
Take alprazolam exactly as prescribed, at evenly spaced intervals throughout the day (for immediate-release tablets) or once daily in the morning (for extended-release tablets). Do not crush, chew, or break extended-release tablets. Do not increase your dose without medical advice, even if you feel the current dose is less effective. Store securely — alprazolam is a controlled substance that should never be shared.
Drowsiness & Impaired Coordination
Tell patient
Sedation is the most common side effect and usually improves within 1–2 weeks. Until you know how alprazolam affects you, do not drive, operate machinery, or perform tasks requiring full alertness. Alcohol must be completely avoided as it greatly increases sedation and breathing risks.
Call prescriber
If sedation does not improve after 2 weeks, if you experience falls, or if you notice slurred speech or significant clumsiness.
Dependence & Withdrawal
Tell patient
Your body can become physically dependent on alprazolam, even at prescribed doses. This does not mean you are addicted, but it does mean that stopping suddenly can be dangerous and may cause seizures. Never stop taking alprazolam on your own — your doctor will create a gradual dose-reduction plan when it is time to stop.
Call prescriber
If you experience shaking, sweating, racing heart, severe anxiety, insomnia, or confusion — these may be signs of withdrawal and need immediate medical attention.
Memory & Cognitive Effects
Tell patient
Some difficulty with memory, particularly for new information, is expected. This effect may not improve significantly over time, unlike sedation. Inform your employer or educational institution if performance is affected.
Call prescriber
If memory problems significantly impact daily functioning, work, or relationships.
Mood Changes
Tell patient
In rare cases, alprazolam can cause unexpected mood changes including irritability, agitation, hostility, or worsened depression. Family members should also be aware of these possibilities.
Call prescriber
Immediately if you have thoughts of self-harm, experience rage or aggression, or if family members notice significant behavioural changes.
Pregnancy & Breastfeeding
Tell patient
Alprazolam crosses the placenta and can cause sedation and withdrawal symptoms in newborns if taken during late pregnancy. Breastfeeding is not recommended during treatment.
Call prescriber
Immediately if you become pregnant or are planning pregnancy, so that a safe transition plan can be arranged.
Storage & Safety
Tell patient
Store at room temperature (20–25°C). Keep in a secure location away from children and anyone for whom it was not prescribed. Alprazolam is a controlled substance — sharing is illegal and dangerous. Dispose of unused tablets safely through a take-back programme.
Call prescriber
If medication is lost, stolen, or you suspect someone else has accessed your supply.
Sources
Regulatory (PI / SmPC)
- XANAX (alprazolam) tablets, for oral use, CIV. Full Prescribing Information. Viatris Specialty LLC. Revised January 2023. FDA Label Primary source for all dosing, adverse reactions, pharmacokinetic data, boxed warnings, and contraindications cited in this monograph.
- XANAX XR (alprazolam) extended-release tablets, for oral use, CIV. Full Prescribing Information. Viatris Specialty LLC. Revised January 2023. FDA Label (XR section) Source for XR-specific dosing, adverse reaction incidence data (Table 2), and discontinuation rates in the XR formulation.
- Alprazolam tablets, for oral use, CIV. Full Prescribing Information (Generic). DailyMed / NLM. DailyMed Generic label providing cross-reference for dosing recommendations in geriatric and hepatic impairment populations.
Key Clinical Trials
- Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45(5):413-422. DOI Landmark Cross-National Collaborative Panic Study establishing alprazolam efficacy in panic disorder; mean effective dose 5–6 mg/day.
- Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry. 1988;45(5):429-436. DOI Documented discontinuation difficulties with alprazolam; 7–29% of patients unable to taper fully.
- Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990;47(10):899-907. DOI Key study documenting withdrawal symptom profiles and severity following abrupt benzodiazepine discontinuation.
Guidelines
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder. 2nd ed. APA; 2009. DOI APA guideline positioning benzodiazepines as adjunctive or second-line agents for panic disorder after SSRIs/SNRIs.
- National Institute for Health and Care Excellence (NICE). Generalised anxiety disorder and panic disorder in adults: management. Clinical guideline [CG113]. Updated 2020. NICE UK guideline recommending against routine benzodiazepine use in GAD except for short-term crisis intervention.
Mechanistic / Basic Science
- Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov. 2011;10(9):685-697. DOI Comprehensive review of GABA-A receptor subtype pharmacology explaining the basis for benzodiazepine anxiolytic vs sedative effects.
- Sigel E, Ernst M. The benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci. 2018;39(7):659-671. DOI Detailed structural analysis of the benzodiazepine binding site informing understanding of allosteric modulation.
Pharmacokinetics / Special Populations
- George TT, Tripp J. Alprazolam. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. Updated April 24, 2023. NCBI Bookshelf Clinician-oriented review summarising pharmacokinetics, special population considerations, and adverse effect profile.
- Greenblatt DJ, Wright CE. Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet. 1993;24(6):453-471. DOI Definitive PK review documenting age-related, obesity-related, and hepatic disease-related changes in alprazolam clearance and half-life.